A Review of Safety, Efficacy, and Utilization of Erythropoietin, Darbepoetin, and Peginesatide for Patients with Cancer or Chronic Kidney Disease: A Report from the Southern Network on Adverse Reactions (SONAR)
暂无分享,去创建一个
J. Armitage | I. Macdougall | C. Bennett | M. Tallman | D. Raisch | O. Sartor | D. Goldsmith | S. Lai | Z. Qureshi | D. Spiegel | L. Norris | S. Silver | S. Smith | Alanna Murday
[1] J. Stockman. Meta-analysis: Erythropoiesis-Stimulating Agents in Patients With Chronic Kidney Disease , 2012 .
[2] M. Hernán,et al. High doses of epoetin do not lower mortality and cardiovascular risk among elderly hemodialysis patients with diabetes. , 2011, Kidney international.
[3] A. Covic,et al. Significant further evidence to bolster the link between epoetin and strokes in chronic kidney disease and cancer. , 2011, Kidney international.
[4] W. McClellan,et al. Changes in erythropoiesis-stimulating agent (ESA) dosing and haemoglobin levels in US non-dialysis chronic kidney disease patients between 2005 and 2009. , 2011, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[5] M. Somerfield,et al. American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] I. Macdougall,et al. Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the Trial to reduce cardiovascular events with Aranesp therapy (TREAT) study. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[7] P. McFarlane,et al. International trends in erythropoietin use and hemoglobin levels in hemodialysis patients. , 2010, Kidney international.
[8] J. Armitage,et al. Reassessments of ESAs for cancer treatment in the US and Europe. , 2010, Oncology.
[9] S. Solomon,et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. , 2009, The New England journal of medicine.
[10] M. Aapro,et al. Update on erythropoiesis-stimulating agents and clinical trials in oncology. , 2009, The oncologist.
[11] M. Tonelli,et al. Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis , 2009, Canadian Medical Association Journal.
[12] M. Zwahlen,et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials , 2009, The Lancet.
[13] M. Tonelli,et al. Introduction to the Canadian Society of Nephrology clinical practice guidelines for the management of anemia associated with chronic kidney disease. , 2008, Kidney international. Supplement.
[14] J. Glaspy. Erythropoiesis-stimulating agents in oncology. , 2008, Journal of the National Comprehensive Cancer Network : JNCCN.
[15] D. Dorr,et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. , 2008, JAMA.
[17] M. Somerfield,et al. Guideline summary: use of epoetin and darbepoetin in patients with cancer-2007 american society of clinical oncology/american society of hematology clinical practice guideline update. , 2008, Journal of oncology practice.
[18] M. Somerfield,et al. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update. , 2008, Blood.
[19] Kdoqi. KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. , 2007 .
[20] J Raftery,et al. A systematic review and economic evaluation of epoetin alpha, epoetin beta and darbepoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatment. , 2007, Health technology assessment.
[21] H. Krum,et al. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis , 2007, The Lancet.
[22] V. Prasad. Correction of Anemia with Epoetin Alfa in Chronic Kidney Disease , 2007 .
[23] H. Burger,et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. , 2006, The New England journal of medicine.
[24] Kdoqi Disclaimer,et al. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. , 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[25] D. Scharfstein,et al. Hematocrit was not validated as a surrogate end point for survival among epoetin-treated hemodialysis patients. , 2004, Journal of clinical epidemiology.
[26] C. Rübe,et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial , 2003, The Lancet.
[27] Brian Leyland-Jones,et al. Breast cancer trial with erythropoietin terminated unexpectedly. , 2003, The Lancet. Oncology.
[28] A R Nissenson,et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. , 1998, The New England journal of medicine.
[29] S. Perry. Report from the Medical Technology and Practice Patterns Institute (MTPPI) , 1995, International Journal of Technology Assessment in Health Care.
[30] Guoxiang Shen. CENTER FOR DRUG EVALUATION AND RESEARCH , 2020 .